Truth or dare: switching BRAF/MEK inhibitors after acute interstitial nephritis in a patient with metastatic melanoma – A case report and review of the literature-Reference-Cited by-同舟云学术

Truth or dare: switching BRAF/MEK inhibitors after acute interstitial nephritis in a patient with metastatic melanoma – A case report and review of the literature

Published:2022-08-23 Issue:3 Volume:78 Page:215-222
ISSN:1784-3286
Container-title:Acta Clinica Belgica
language:en
Short-container-title:Acta Clinica Belgica

Author:

De Ryck Lore¹^ORCID,Delanghe Sigurd²,Jacobs Celine¹,Fadaei Sharareh³,Brochez Lieve⁴,Saerens Michael¹

Affiliation:

1. Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium

2. Department of Nephrology, Ghent University Hospital, Ghent, Belgium

3. Department of Anatomopathology, Ghent University Hospital, Ghent, Belgium

4. Department of Dermatology, Ghent University Hospital, Ghent, Belgium

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17843286.2022.2114684

Reference41 articles.

1. Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019

2. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

3. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

4. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

5. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dabrafenib/trametinib;Reactions Weekly;2023-05-27